Literature DB >> 9143687

Fc receptor biology.

M Daëron1.   

Abstract

This review deals with membrane Fc receptors (FcR) of the immunoglobulin superfamily. It is focused on the mechanisms by which FcR trigger and regulate biological responses of cells on which they are expressed. FcR deliver signals when they are aggregated at the cell surface. The aggregation of FcR having immunoreceptor tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases and syk family tyrosine kinases that connect transduced signals to common activation pathways shared with other receptors. FcR with ITAMs elicit cell activation, endocytosis, and phagocytosis. The nature of responses depends primarily on the cell type. The aggregation of FcR without ITAM does not trigger cell activation. Most of these FcR internalize their ligands, which can be endocytosed, phagocytosed, or transcytosed. The fate of internalized receptor-ligand complexes depends on defined sequences in the intracytoplasmic domain of the receptors. The coaggregation of different FcR results in positive or negative cooperation. Some FcR without ITAM use FcR with ITAM as signal transduction subunits. The coaggregation of antigen receptors or of FcR having ITAMs with FcR having immunoreceptor tyrosine-based inhibition motifs (ITIMs) negatively regulates cell activation. FcR therefore appear as the subunits of multichain receptors whose constitution is not predetermined and which deliver adaptative messages as a function of the environment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143687     DOI: 10.1146/annurev.immunol.15.1.203

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  286 in total

1.  Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling.

Authors:  S Lemay; D Davidson; S Latour; A Veillette
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 2.  Epithelial transcytosis of immunoglobulins.

Authors:  W Hunziker; J P Kraehenbuhl
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-07       Impact factor: 2.673

3.  Sequential requirements of the N-terminal palmitoylation site and SH2 domain of Src family kinases in the initiation and progression of FcepsilonRI signaling.

Authors:  Z i Honda; T Suzuki; H Kono; M Okada; T Yamamoto; C Ra; Y Morita; K Yamamoto
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  Total internal reflection with fluorescence correlation spectroscopy: combined surface reaction and solution diffusion.

Authors:  T E Starr; N L Thompson
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

5.  Mutant RBL mast cells defective in Fc epsilon RI signaling and lipid raft biosynthesis are reconstituted by activated Rho-family GTPases.

Authors:  K A Field; J R Apgar; E Hong-Geller; R P Siraganian; B Baird; D Holowka
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 6.  Review article: ageing and the neutrophil: no appetite for killing?

Authors:  S Butcher; H Chahel; J M Lord
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

7.  Genome-wide detection of alternative splicing in expressed sequences of human genes.

Authors:  B Modrek; A Resch; C Grasso; C Lee
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

Review 8.  Functions of antibodies in the regulation of B cell responses in vivo.

Authors:  B Heyman
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 9.  Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.

Authors:  S Izui; L Fossati-Jimack; S A da Silveira; T Moll
Journal:  Springer Semin Immunopathol       Date:  2001-12

10.  Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis.

Authors:  James W Booth; Moo-Kyung Kim; Andrzej Jankowski; Alan D Schreiber; Sergio Grinstein
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.